【星昊医药:双鹭药业拟减持不高于1.51%公司股份】星昊医药公告,持股5%以上股东北京双鹭药业股份有限公司计划减持不超过185万股,占公司总股本的1.51%。减持方式为集中竞价或大宗交易,减持期间为公告披露之日起30个交易日后的三个月内。减持价格将根据减持时的二级市场价格确定,减持原因为资金需求。

金融界
Jun 03, 2025
星昊医药公告,持股5%以上股东北京双鹭药业股份有限公司计划减持不超过185万股,占公司总股本的1.51%。减持方式为集中竞价或大宗交易,减持期间为公告披露之日起30个交易日后的三个月内。减持价格将根据减持时的二级市场价格确定,减持原因为资金需求。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10